The Diagnostic Approach to Hyperkalemia - Flowchart
The Diagnostic Approach to Hyperkalemia - Flowchart
«Flowchart»

Hyperkalemia (Serum K+ 5.5 mmol/l)

Hyperkalemia (Serum K+ 5.5 mmol/l)

Hyperkalemia (Serum K+ 5.5 mmol/l)

+

K+ 6.0 or ECG changes

K+ 6.0 or ECG changes

+ K+<img border="0" src="../Z/tu0.gif"></img>6.0

Pseudohyperkalemia?

Pseudohyperkalemia?

Pseudohyperkalemia?

No further action

No further action

No further action

Treat accordingly and re-evaluate

Treat accordingly and re-evaluate

Treat accordingly and re-evaluate

Treat accordingly and re-evaluate*

Treat accordingly and re-evaluate*

Treat accordingly and re-evaluate*

* *

Decreased urinary K+ excretion (<40 mmol/d)

Decreased urinary K+ excretion (<40 mmol/d)

Decreased urinary K+ excretion (<40 mmol/d)

+

Decreased distal Na+ delivery

Decreased distal Na+ delivery

Decreased distal Na+ delivery

+

Reduced distal K+ secretion (GFR >20 mL/min)

Reduced distal K+ secretion (GFR >20 mL/min)

Reduced distal K+ secretion (GFR >20 mL/min)

+

Drugs


Amiloride
Spironolactone
Triamterene
Trimethoprim
Pentamidine
Eplerenone
Drospirenone
Calcineurin inhibitors

Other causes


Tubulointerstitial diseases
Urinary tract obstruction
PHA type I
PHA type II
Sickle cell disease
Renal transplant
SLE

Drugs


Amiloride
Spironolactone
Triamterene
Trimethoprim
Pentamidine
Eplerenone
Drospirenone
Calcineurin inhibitors

Other causes


Tubulointerstitial diseases
Urinary tract obstruction
PHA type I
PHA type II
Sickle cell disease
Renal transplant
SLE

Drugs

Drugs


Amiloride
Spironolactone
Triamterene
Trimethoprim
Pentamidine
Eplerenone
Drospirenone
Calcineurin inhibitors


Amiloride
Spironolactone
Triamterene
Trimethoprim
Pentamidine
Eplerenone
Drospirenone
Calcineurin inhibitors

Other causes

Other causes


Tubulointerstitial diseases
Urinary tract obstruction
PHA type I
PHA type II
Sickle cell disease
Renal transplant
SLE


Tubulointerstitial diseases
Urinary tract obstruction
PHA type I
PHA type II
Sickle cell disease
Renal transplant
SLE

Low aldosterone

Low aldosterone

Low aldosterone

Emergency therapy

Emergency therapy

Emergency therapy

K+ 6.0 or ECG changes

K+ 6.0 or ECG changes

+ K[+]

Pseudohypokalemia?

Pseudohypokalemia?

Pseudohypokalemia?

Yes

Yes

Yes

No

No

No

Yes

Yes

Yes

No

No

No

Yes

Yes

Yes

No

No

No

Urine electrolytes

Urine electrolytes

Urine electrolytes

Urine Na+ <25 mmol/L

Urine Na+ <25 mmol/L

+ Urine

TTKG

TTKG

TTKG

>8

>8

>8

<5

<5

<5

Emergency therapy

Emergency therapy

Emergency therapy

End

End

End

Yes

Yes

Yes

No

No

No

End

End

End

End

End

End

End

End

End

End

End

End

Reduced tubular flow

Reduced tubular flow

Reduced tubular flow

Advanced kidney failure (GFR 20 mL/min)

Advanced kidney failure (GFR 20 mL/min)

Advanced

Reduced ECV

Reduced ECV

Reduced

End

End

End

End

End

End

9α-Fludrocortisone

9α-Fludrocortisone

9α-Fludrocortisone

α

TTKG <8 (tubular resistance)

TTKG <8 (tubular resistance)

TTKG <8 (tubular resistance)

TTKG 8

TTKG 8

TTKG Greater than equal to 8

End

End

End

Renin

Renin

Renin

High


Primary adrenal insufficiency
Isolated aldosterone deficiency
Heparin/LMW heparin
ACE-l/ARB
Ketoconazole

High


Primary adrenal insufficiency
Isolated aldosterone deficiency
Heparin/LMW heparin
ACE-l/ARB
Ketoconazole


Primary adrenal insufficiency
Isolated aldosterone deficiency
Heparin/LMW heparin
ACE-l/ARB
Ketoconazole High

Low


Diabetes mellitus
Acute GN
Tubulointerstitial diseases
PHA type II
NSAIDs
β-Blockers

Low


Diabetes mellitus
Acute GN
Tubulointerstitial diseases
PHA type II
NSAIDs
β-Blockers


Diabetes mellitus
Acute GN
Tubulointerstitial diseases
PHA type II
NSAIDs
β-Blockers β Low

End

End

End

End

End

End

History, physical examination and basic laboratory tests

History, physical examination and basic laboratory tests

History, physical examination and basic laboratory tests

Evidence of increased K+ load

Evidence of increased K+ load

+ Increased potassium

Evidence of transcellular shift:

Evidence of transcellular shift:

Transcellular shift


Hypertonicity (e.g., mannitol)
Hyperglycemia
Succinylcholine
-aminocaproic acid
Digoxin
β-Blockers
Metabolic acidosis (nonorganic)
Arginine infusion
Hyperkalemic periodic paralysis
Insulin
Exercise


Hypertonicity (e.g., mannitol)
Hyperglycemia
Succinylcholine
-aminocaproic acid
Digoxin
β-Blockers
Metabolic acidosis (nonorganic)
Arginine infusion
Hyperkalemic periodic paralysis
Insulin
Exercise


Hypertonicity (e.g., mannitol)
Hyperglycemia
Succinylcholine
-aminocaproic acid
Digoxin
β-Blockers
Metabolic acidosis (nonorganic)
Arginine infusion
Hyperkalemic periodic paralysis
Insulin
Exercise


Hypertonicity (e.g., mannitol)
Hyperglycemia
Succinylcholine
-aminocaproic acid
Digoxin
β-Blockers β
Metabolic acidosis (nonorganic)
Arginine infusion
Hyperkalemic periodic paralysis
Insulin
Exercise

Yes

Yes

Yes

No

No

No